Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 14/20 | 1.00 |
| ▸ | S1PR1 | P21453 | 8/20 | 1.00 |
| ▸ | S1PR3 | Q99500 | 6/20 | 1.00 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL322452 | 0.95 | S1PR5 (1.00) | S1PR5S1PR1S1PR3BCHEACHE | |
| SCHEMBL320868 | 0.91 | S1PR5 (0.88) | S1PR5S1PR1S1PR3 | |
| SCHEMBL15153928 | 0.89 | S1PR5 (0.79) | S1PR5S1PR1S1PR3BCHEACHE | |
| SCHEMBL320659 | 0.85 | S1PR5 (0.79) | S1PR5S1PR1S1PR3BCHEACHE | |
| SCHEMBL15909397 | 0.78 | S1PR5 (1.00) | S1PR5S1PR1S1PR3FFAR1 | |
| SCHEMBL15164301 | 0.77 | S1PR5 (0.69) | S1PR5S1PR1S1PR3 | |
| SCHEMBL18550086 | 0.76 | S1PR5 (0.67) | S1PR5S1PR1S1PR3FFAR1 | |
| SCHEMBL20671099 | 0.72 | S1PR5 (0.56) | S1PR5S1PR1S1PR3 | |
| SCHEMBL320912 | 0.71 | S1PR5 (0.65) | S1PR5S1PR1S1PR3FFAR4FFAR1 | |
| SCHEMBL18550351 | 0.70 | S1PR5 (0.60) | S1PR5S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE48301-E1 | Fused heterocyclic derivatives as S1P modulators | ABBVIE B.V. (NL) | 2020-11-10 | — | — | US | claimed |
| EP-2590980-B1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | ABBVIE BV (NL) | 2017-09-20 | — | — | EP | claimed |
| US-9670220-B2 | Fused heterocyclic derivatives as S1P modulators | ABBVIE B.V. (NL) | 2017-06-06 | — | — | US | claimed |
| US-20150284403-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-10-08 | — | — | US | claimed |
| US-9096612-B2 | Fused heterocyclic derivatives as S1P modulators | ABBVIE B.V. (NL) | 2015-08-04 | — | — | US | claimed |
| US-8796262-B2 | Fused heterocyclic derivatives as S1P modulators | ABBVIE B.V. (NL) | 2014-08-05 | — | — | US | claimed |
| US-20140066433-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | ABBVIE INC (US) | 2014-03-06 | — | — | US | claimed |
| US-20130203737-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2013-08-08 | — | — | US | claimed |
| US-RE48301-E1 | Fused heterocyclic derivatives as S1P modulators | ABBVIE B.V. (NL) | 2020-11-10 | — | — | US | disclosed |
| EP-2590980-B1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | ABBVIE BV (NL) | 2017-09-20 | — | — | EP | disclosed |
| US-9670220-B2 | Fused heterocyclic derivatives as S1P modulators | ABBVIE B.V. (NL) | 2017-06-06 | — | — | US | disclosed |
| US-20150284403-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-10-08 | — | — | US | disclosed |
| US-9096612-B2 | Fused heterocyclic derivatives as S1P modulators | ABBVIE B.V. (NL) | 2015-08-04 | — | — | US | disclosed |
| US-8796262-B2 | Fused heterocyclic derivatives as S1P modulators | ABBVIE B.V. (NL) | 2014-08-05 | — | — | US | disclosed |
| US-20140066433-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | ABBVIE INC (US) | 2014-03-06 | — | — | US | disclosed |
| US-20130203737-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2013-08-08 | — | — | US | disclosed |
| EP-2590980-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012004373-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066433-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | S1PR5, S1PR1, S1PR3 | S1PR5 1/4885S1PR1 2/4885S1PR3 3/4885 |
| US-20130203737-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | S1PR3, S1PR1, S1PR2 | S1PR5 5/4885S1PR1 2/4885S1PR3 1/4885 |
| US-20150284403-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | S1PR5, S1PR1, S1PR3 | S1PR5 1/4885S1PR1 2/4885S1PR3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.